168 related articles for article (PubMed ID: 24584025)
21. Clinical and Microbiological Characteristics of Breakthrough Candidemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital.
Kimura M; Araoka H; Yamamoto H; Asano-Mori Y; Nakamura S; Yamagoe S; Ohno H; Miyazaki Y; Abe M; Yuasa M; Kaji D; Kageyama K; Nishida A; Ishiwata K; Takagi S; Yamamoto G; Uchida N; Izutsu K; Wake A; Taniguchi S; Yoneyama A
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115352
[TBL] [Abstract][Full Text] [Related]
22. Antifungal lock therapy with combined 70% ethanol and micafungin in a critically ill infant.
Piersigilli F; Auriti C; Bersani I; Goffredo B; Bianco G; Savarese I; Dotta A
Pediatr Infect Dis J; 2014 Apr; 33(4):419-20. PubMed ID: 24637514
[TBL] [Abstract][Full Text] [Related]
23. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.
Shorr AF; Wu C; Kothari S
J Antimicrob Chemother; 2011 Feb; 66(2):375-80. PubMed ID: 21147825
[TBL] [Abstract][Full Text] [Related]
24. Micafungin use in children.
Emiroglu M
Expert Rev Anti Infect Ther; 2011 Sep; 9(9):821-34. PubMed ID: 21905789
[TBL] [Abstract][Full Text] [Related]
25. Safety of high-dose micafungin for patients with hematological diseases.
Yamazaki S; Nakamura F; Yoshimi A; Ichikawa M; Nannya Y; Kurokawa M
Leuk Lymphoma; 2014 Nov; 55(11):2572-6. PubMed ID: 24460099
[TBL] [Abstract][Full Text] [Related]
26. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.
Ostrosky-Zeichner L; Kontoyiannis D; Raffalli J; Mullane KM; Vazquez J; Anaissie EJ; Lipton J; Jacobs P; van Rensburg JH; Rex JH; Lau W; Facklam D; Buell DN
Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):654-61. PubMed ID: 16261306
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of recurrent candidemia due to candidal thrombophlebitis associated with a central venous catheter using a combination of fosfluconazole and micafungin.
Hagiya H; Kajioka H
Intern Med; 2013; 52(18):2139-43. PubMed ID: 24042529
[TBL] [Abstract][Full Text] [Related]
28. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy.
Natarajan G; Lulic-Botica M; Aranda JV
J Perinatol; 2009 Nov; 29(11):738-43. PubMed ID: 19776753
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.
Undre NA; Stevenson P; Freire A; Arrieta A
Pediatr Infect Dis J; 2012 Jun; 31(6):630-2. PubMed ID: 22301478
[TBL] [Abstract][Full Text] [Related]
30. Effects of empiric antifungal therapy for septic shock on time to appropriate therapy for Candida infection: a pilot study.
Micek ST; Arnold H; Juang P; Hampton N; McKenzie M; Scolarici M; Kollef M
Clin Ther; 2014 Sep; 36(9):1226-32. PubMed ID: 25064625
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis.
Kale-Pradhan PB; Morgan G; Wilhelm SM; Johnson LB
Pharmacotherapy; 2010 Dec; 30(12):1207-13. PubMed ID: 21114387
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK.
Sidhu MK; van Engen AK; Kleintjens J; Schoeman O; Palazzo M
Curr Med Res Opin; 2009 Aug; 25(8):2049-59. PubMed ID: 19575628
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.
Kohno S; Masaoka T; Yamaguchi H; Mori T; Urabe A; Ito A; Niki Y; Ikemoto H
Scand J Infect Dis; 2004; 36(5):372-9. PubMed ID: 15287383
[TBL] [Abstract][Full Text] [Related]
34. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.
Masterton RG; Casamayor M; Musingarimi P; van Engen A; Zinck R; Odufowora-Sita O; Odeyemi IA
J Med Econ; 2013 Nov; 16(11):1344-56. PubMed ID: 24003830
[TBL] [Abstract][Full Text] [Related]
35. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial.
Timsit JF; Azoulay E; Cornet M; Gangneux JP; Jullien V; Vésin A; Schir E; Wolff M
Trials; 2013 Nov; 14():399. PubMed ID: 24261608
[TBL] [Abstract][Full Text] [Related]
36. Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients.
Suh JW; Kim SB; Yoon YK; Sohn JW; Kim MJ; Kim JH
Mycopathologia; 2020 Aug; 185(4):653-664. PubMed ID: 32705415
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
38. Echinocandin use in the neonatal intensive care unit.
Caudle KE; Inger AG; Butler DR; Rogers PD
Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
[TBL] [Abstract][Full Text] [Related]
39. [Activity of micafungin against Candida biofilms].
Quindós G; Villar-Vidal M; Eraso E
Rev Iberoam Micol; 2009 Mar; 26(1):49-55. PubMed ID: 19463277
[TBL] [Abstract][Full Text] [Related]
40. Breakthrough fungemia due to Candida fermentati with fks1p mutation under micafungin treatment in a cord blood transplant recipient.
Konuma T; Takahashi S; Kiyuna T; Miharu Y; Suzuki M; Shibata H; Kato S; Takahashi S; Tojo A
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27859978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
